EQS-Adhoc: QIAGEN N.V.: QIAGEN announces strong preliminary Q1 2025 results and updates full-year 2025 adjusted earnings per share outlook
|
EQS-Ad-hoc: QIAGEN N.V. / Key word(s): Preliminary Results Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN announces strong preliminary Q1 2025 results and updates full-year 2025 adjusted earnings per share outlook Venlo, the Netherlands, April 6, 2025 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces preliminary Q1 2025 results that exceed the outlook for both net sales and adjusted earnings per share (EPS), and also updates its adjusted EPS outlook for full-year 2025, reflecting strong performances across many growth drivers. Net sales grew approximately 5% (+7% at constant exchange rates, CER) to about $483 million in Q1 2025, surpassing the previously communicated outlook for about 3% CER growth (4% CER core business excluding discontinued products such as NeuMoDx and Dialunox). Adjusted diluted EPS are expected to be at least $0.55 CER compared to the previously communicated outlook for about $0.50 CER. Sales of the QuantiFERON latent TB test grew about 15% CER as global adoption continues to shift from the skin test to this proven, modern blood-based test. The QIAstat-Dx syndromic testing system advanced above 35% CER on continued demand for respiratory panels along with growth in gastrointestinal and meningitis testing. The QIAcuity digital PCR system and QIAGEN Digital Insights bioinformatics business both delivered high-single-digit CER gains, reflecting solid adoption across research and clinical applications. Additional growth contributions also came from higher sales of PCR consumables and from OEM products. Sample technologies sales declined 1% CER, reflecting the cautious instrument spending environment among some Life Sciences customers. Given the positive start to 2025, QIAGEN is raising its adjusted diluted EPS outlook for full-year 2025 in light of the strong sales growth in Q1 and the overall current business trends, which includes expected headwinds from the recently announced U.S. import tariffs and a better-than-expected tax environment. Full-year 2025, adjusted diluted EPS are now expected to be about $2.35 CER, up from the prior full-year outlook for about $2.28 CER, while reaffirming the goal to improve the adjusted operating income margin to above 30% for the year.
QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands
ISIN: NL0015002CX3 Frankfurt Stock Exchange, Regulated Market (Prime Standard)
John Gilardi, Tel: +49 2103 29 11711; john.gilardi@qiagen.com
End of Inside Information
06-Apr-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | QIAGEN N.V. |
| Hulsterweg 82 | |
| 5912 PL Venlo | |
| Netherlands | |
| Phone: | +31 7735566 - 00 |
| Fax: | +31 77 35566-58 |
| E-mail: | qiagen@qiagen.com |
| Internet: | www.qiagen.com |
| ISIN: | NL0015002CX3 |
| WKN: | A40ZZU |
| Indices: | DAX, TecDAX |
| Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE, SIX |
| EQS News ID: | 2112196 |
| End of Announcement | EQS News Service |
|
|
2112196 06-Apr-2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 1.362,88 | 1.527,26 | 1.985,15 | 2.007,10 | 1.780,48 | 1.898,98 | 0,00 | |
| EBITDA1,2 | 183,32 | 482,95 | 753,93 | 697,99 | 565,68 | 288,92 | 0,00 | |
| EBITDA-Margin3 | 13,45 | 31,62 | 37,98 | 34,78 | 31,77 | 15,21 | 0,00 | |
| EBIT1,4 | -23,34 | 315,55 | 560,44 | 499,50 | 374,22 | 93,80 | 0,00 | |
| EBIT-Margin5 | -1,71 | 20,66 | 28,23 | 24,89 | 21,02 | 4,94 | 0,00 | |
| Net Profit (Loss)1 | -37,01 | 293,30 | 473,49 | 539,15 | 439,21 | 80,24 | 0,00 | |
| Net-Margin6 | -2,72 | 19,20 | 23,85 | 26,86 | 24,67 | 4,23 | 0,00 | |
| Cashflow1,7 | 295,40 | 373,83 | 595,98 | 703,48 | 446,44 | 646,57 | 0,00 | |
| Earnings per share8 | -0,16 | 1,25 | 2,31 | 2,34 | 1,90 | 0,36 | 1,80 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,22 | 0,25 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Qiagen | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A40ZZU | NL0015002CX3 | N.V. | 8.724,81 Mio € | 25.09.1997 | Halten | 9F385X9M+R4 |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 20,04 | 25,10 | 0,80 | 31,17 | 2,58 | 13,49 | 4,59 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,22 | 0,25 | 0,62% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 26.06.2025 | 08.05.2025 | 05.08.2025 | 13.11.2025 | 05.02.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +1,06% | +1,78% | -9,31% | -6,22% | +1.254,01% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
